We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-19.4%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.07B
AUM Growth
-$277M
(-12%)
Cap. Flow
+$203M
Cap. Flow
% of AUM
9.83%
Top 10 Holdings %
Top 10 Hldgs %
48.47%
Holding
98
New
23
Increased
27
Reduced
24
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$50.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$48.9M |
| 3 |
SHPG
Shire pic
SHPG
|
+$40.3M |
| 4 |
CELG
Celgene Corp
CELG
|
+$33.1M |
| 5 |
Amgen
AMGN
|
+$26.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$57.3M |
| 2 |
Halozyme
HALO
|
+$36M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$31.7M |
| 4 |
United Therapeutics
UTHR
|
+$30.6M |
| 5 |
Merck
MRK
|
+$19.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $150M | 7.25% |
1,498,738
+321,680
| +27% | +$33.1M |
|
2
Gilead Sciences
GILD
$167B
| $149M | 7.23% |
1,626,764
-155,534
| -9% | -$14M |
|
3
BioMarin Pharmaceuticals
BMRN
$11.5B
| $123M | 5.94% |
1,489,137
+129,215
| +10% | +$10.5M |
|
|
4
Amgen
AMGN
$198B
| $102M | 4.95% |
682,797
+178,200
| +35% | +$26.5M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
| $91.5M | 4.42% |
657,013
-101,167
| -13% | -$14.9M |
|
6
Regeneron Pharmaceuticals
REGN
$70.9B
| $83.9M | 4.06% |
232,770
-3,530
| -1% | -$1.45M |
|
7
Incyte
INCY
$23.4B
| $83.6M | 4.04% |
1,153,540
+26,117
| +2% | +$1.95M |
|
|
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
| $78M | 3.77% |
9,226,145
+1,252,709
| +16% | +$8.87M |
|
9
Vertex Pharmaceuticals
VRTX
$123B
| $71.3M | 3.45% |
896,479
+208,279
| +30% | +$18.8M |
|
|
SHPG
10
DELISTED
Shire pic
SHPG
| $69.7M | 3.37% |
405,347
+240,673
| +146% | +$40.3M |
|
|
11
Neurocrine Biosciences
NBIX
$17.2B
| $65.3M | 3.16% |
1,649,963
+1,233,283
| +296% | +$48.9M |
|
12
Biogen
BIIB
$30.4B
| $61.1M | 2.95% |
234,572
-56,317
| -19% | -$14.9M |
|
|
13
Thermo Fisher Scientific
TMO
$198B
| $52.4M | 2.54% |
370,376
-236,560
| -39% | -$31.7M |
|
|
14
Merck
MRK
$315B
| $39.7M | 1.92% |
785,910
-389,867
| -33% | -$19.1M |
|
15
DexCom
DXCM
$29.6B
| $38.8M | 1.88% |
2,286,236
+835,304
| +58% | +$14M |
|
|
XLRN
16
DELISTED
Acceleron Pharma
XLRN
| $37.9M | 1.83% |
1,437,235
+315,971
| +28% | +$9.19M |
|
17
Eli Lilly
LLY
$1.05T
| $36.5M | 1.76% |
506,695
-92,550
| -15% | -$7M |
|
18
Medtronic
MDT
$106B
| $35.7M | 1.73% |
475,931
-67,861
| -12% | -$5.11M |
|
|
PTLA
19
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $32.5M | 1.57% |
+1,593,039
| New | +$50.5M |
|
|
ALDR
20
DELISTED
Alder Biopharmaceuticals
ALDR
| $31.6M | 1.53% |
1,291,153
+356,202
| +38% | +$8.25M |
|
|
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $31.5M | 1.52% |
245,447
+25,400
| +12% | +$3M |
|
22
Align Technology
ALGN
$12.7B
| $30.7M | 1.48% |
422,486
+36,382
| +9% | +$2.38M |
|
|
TSRO
23
DELISTED
TESARO, Inc.
TSRO
| $30.4M | 1.47% |
689,869
+284,800
| +70% | +$11.4M |
|
24
Viatris
VTRS
$20.1B
| $27.3M | 1.32% |
589,627
-12,283
| -2% | -$593K |
|
25
Teva Pharmaceuticals
TEVA
$37.3B
| $27.2M | 1.32% |
509,110
-96,812
| -16% | -$5.68M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q1 2016 Portfolio in Review
As of Q1 2016, Sectoral Asset Management held 98 positions worth $2.07B, down 12% from $2.35B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Sectoral Asset Management deployed $203M of net new capital in Q1 2016, opening 23 new positions and adding to 27 existing holdings. Its largest new stake was Portola Pharmaceuticals, Inc.: 1,593,039 shares worth $32.5M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier.
On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $31.7M trimmed.
- Sectoral Asset Management's largest Q1 2016 buy was Portola Pharmaceuticals, Inc.: 1,593,039 shares worth $32.5M.
- Sectoral Asset Management added most to Neurocrine Biosciences in Q1 2016, an estimated $48.9M increase.
- Sectoral Asset Management's biggest Q1 2016 reduction was Thermo Fisher Scientific, cutting an estimated $31.7M.
- Sectoral Asset Management fully exited Seagen Inc. Common Stock in Q1 2016, selling an estimated $57.3M.
- Sectoral Asset Management's ten largest holdings make up 48% of its $2.07B portfolio in Q1 2016.
- Sectoral Asset Management opened 23 new positions and closed 17 in Q1 2016.
- Sectoral Asset Management's portfolio value fell 12% quarter-over-quarter to $2.07B.
Based on Sectoral Asset Management's 13F filing for Q1 2016, filed 13 May 2016.